Mineralys Therapeutics

Mineralys Therapeutics, Inc., headquartered in Philadelphia, Pennsylvania, is a privately held clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of hypertension. Through the development of MLS-101, the company aims to introduce a targeted approach to treating hypertension. MLS-101 is a highly selective and potent aldosterone synthase inhibitor currently under investigation for the treatment of hypertension.